Envista (NVST)
(Delayed Data from NYSE)
$17.70 USD
-0.14 (-0.78%)
Updated Oct 15, 2024 04:00 PM ET
After-Market: $17.70 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
B Value B Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$17.70 USD
-0.14 (-0.78%)
Updated Oct 15, 2024 04:00 PM ET
After-Market: $17.70 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
B Value B Growth B Momentum B VGM
Zacks News
Why Envista (NVST) International Revenue Trends Deserve Your Attention
by Zacks Equity Research
Examine Envista's (NVST) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.
Envista (NVST) Q2 Earnings & Revenues Miss, Margins Fall
by Zacks Equity Research
Envista's (NVST) Spark division sales witness a slowdown in the second quarter due to the deferment of a larger portion of case revenues.
Here's What Key Metrics Tell Us About Envista (NVST) Q2 Earnings
by Zacks Equity Research
Although the revenue and EPS for Envista (NVST) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Envista (NVST) Q2 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Envista (NVST) delivered earnings and revenue surprises of -59.26% and 2.30%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Wall Street's Insights Into Key Metrics Ahead of Envista (NVST) Q2 Earnings
by Zacks Equity Research
Get a deeper insight into the potential performance of Envista (NVST) for the quarter ended June 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Canopy Growth Corporation (CGC) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Canopy Growth (CGC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Envista (NVST) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Envista (NVST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Envista (NVST) Down 4.7% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Envista (NVST) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Envista (NVST) Q1 Earnings Miss Estimates, Margins Down
by Zacks Equity Research
Envista (NVST) registers a year-over-year decline in both segments in the first quarter of 2024.
Here's What Key Metrics Tell Us About Envista (NVST) Q1 Earnings
by Zacks Equity Research
The headline numbers for Envista (NVST) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Envista (NVST) Lags Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Envista (NVST) delivered earnings and revenue surprises of -16.13% and 0.87%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Envista (NVST) Faces Macroeconomic Challenges, FX Headwind
by Zacks Equity Research
The challenging macroeconomic conditions are resulting in a significant escalation in Envista's (NVST) costs and expenses.
Envista (NVST) Down 5.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Envista (NVST) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Envista (NVST) Q4 Earnings Miss Estimates, Margins Down
by Zacks Equity Research
Strong performance in the Speciality Products & Technologies segment contributes to Envista's (NVST) Q4 revenues.
Envista (NVST) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
Although the revenue and EPS for Envista (NVST) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Medical Products Stocks' Earnings Due on Feb 7: STE, PAHC & NVST
by Urmimala Biswas
Medical Products companies' quarterly results are likely to reflect a year-over-year decline in earnings. Let's see how STE, PAHC and NVST fare this time.
Curious about Envista (NVST) Q4 Performance? Explore Wall Street Estimates for Key Metrics
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Envista (NVST), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2023.
Haemonetics (HAE) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Haemonetics (HAE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Envista (NVST) Q4 Earnings Expected to Decline
by Zacks Equity Research
Envista (NVST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for December 21st
by Zacks Equity Research
DSKE, NVST and HENKY have been added to the Zacks Rank #5 (Strong Sell) List on December 21, 2023.
Envista (NVST) Up 6.8% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Envista (NVST) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Envista (NVST) Q3 Earnings Miss Estimates, Gross Margin Down
by Zacks Equity Research
Envista's (NVST) Q3 performance is impacted by the negative impact of Russia and the weakness of higher-end specialty procedures in developed markets.
Compared to Estimates, Envista (NVST) Q3 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for Envista (NVST) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
MedTech Stocks' Q3 Earnings Due on Nov 1: IDXX, EXAS & More
by Urmimala Biswas
MedTech companies' third-quarter results are likely to reflect a year-over-year decline. Let's see how IDXX, EXAS, TNDM and NVST fare this time.
Select Medical (SEM) Q2 Earnings Meet, Revenues Rise Y/Y
by Zacks Equity Research
Select Medical's (SEM) Q2 results reflect solid segmental revenues, attributable to higher patient days and outpatient visits. Management projects adjusted EPS of $1.86-$2.03 for 2023.